| Bone loss or lost bone: rationale and recommendations for the diagnosis and treatment of early postmenopausal bone loss. | |
| | |
MedLine Citation:
|
PMID: 19968915 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Recent reports suggest that bone loss begins during late perimenopause at a dramatic rate, even before estrogen levels plummet. During the ensuing 5 years, there is evidence of the beginnings of microarchitectural deterioration, which impacts bone strength and ultimately enhances its propensity to fracture. The diagnosis of osteoporosis based on T-scores alone, or through stratification for a high fracture risk by FRAX, excludes these women who are rapidly losing bone. Because all antiosteoporosis therapies, in particular bisphosphonates, reduce bone loss, we propose aggressive, likely short-term therapy with a goal to reduce bone loss, stabilize bone density, and prevent microarchitectural deterioration. |
| | |
Authors:
|
Mone Zaidi; Charles H Turner; Ernesto Canalis; Roberto Pacifici; Li Sun; Jameel Iqbal; X Edward Guo; Stuart Silverman; Solomon Epstein; Clifford J Rosen |
Related Documents
:
|
11194525 - Nutrition in bone health revisited: a story beyond calcium. 18987295 - Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse eff... 8845585 - Bisphosphonates and the treatment of bone disease in the elderly. 9706225 - The genetics of osteoporosis: vitamin d receptor polymorphisms. 12417165 - Facial reconstruction using the visor scalp flap. 8676735 - One-stage treatment of infected bone defects of the tibia with skin loss by free vascul... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Current osteoporosis reports Volume: 7 ISSN: 1544-2241 ISO Abbreviation: Curr Osteoporos Rep Publication Date: 2009 Dec |
Date Detail:
|
Created Date: 2009-12-08 Completed Date: 2010-02-18 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101176492 Medline TA: Curr Osteoporos Rep Country: United States |
Other Details:
|
Languages: eng Pagination: 118-26 Citation Subset: IM |
Affiliation:
|
The Mount Sinai Bone Program, Box 1055, Mount Sinai School of Medicine, One Gustave Levy Place, New York, NY 10029, USA. mone.zaidi@mssm.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Bone Density Bone Density Conservation Agents / therapeutic use Bone Remodeling Female Fractures, Spontaneous / etiology, prevention & control Humans Osteoporosis, Postmenopausal / diagnosis*, drug therapy*, physiopathology Perimenopause Risk Assessment |
| Chemical | |
Reg. No./Substance:
|
0/Bone Density Conservation Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Osteoporosis prevention and nutrition.
Next Document: Variation in risk factors for fractures at different sites.